Sleeping sickness—a growing problem?BMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7527.1242 (Published 24 November 2005) Cite this as: BMJ 2005;331:1242
- Jean G Jannin, coordinator, innovative and intensified disease management ()1
- 1 Communicable Diseases - Neglected Tropical Diseases Control, World Health Organization, 121 Geneva 27, Switzerland
This Ugandan sleeping sickness research is timely.1 After five years of intensified control, the human African trypanosomiasis landscape has changed. Before 2000, the sleeping sickness epidemic was spreading in Africa. Approximately half a million people living in the poorest areas were expected to be infected by this killer disease. Early detection of cases, before the parasites start to destroy the central nervous system, is essential for effective treatment. This is the only way to avoid using existing potent drugs (melarsoprol) or drugs that are very difficult to administer in remote areas (eflornithine requires an infusion every six hours for 14 days). In 2000, the availability of drugs was threatened and the treatment of patients challenged. The establishment of a large programme based on ensuring access for populations to health facilities, diagnosis, and treatment was conceived. This led to a long term donation of drugs—pentamidine, melarsoprol, eflornithine (Sanofi-Aventis), and suramin (Bayer)—with access to financial support (from Sanofi-Aventis, France and Belgium), which led to a drastic reduction in epidemics, assisted in the training of technicians, and ensured an efficient drug supply system, as well as promoting the use of the most efficient diagnostic tools and mobilising the international community.2 3 Considering the achievements made in the area of control of sleeping sickness, leading to a current reduction of new cases and increase of surveillance activities, the International Scientific Council for Trypanosomiasis Research and Control (at its 28th conference in Addis Ababa in September 2005) recommended that WHO “Launch an elimination programme of sleeping sickness, to adapt control strategies towards this goal and advocate partners who have permanently provided support to maintain their efforts and assistance.”
Elimination of sleeping sickness as a public health problem through use of existing tools for diagnosis and treatment can be considered achievable. However, owing to the lack of safe oral drugs to treat both early and late stages of the disease, the integration of control activities in basic health system might be impossible and may lead to a non-sustainable elimination as it has been seen in the past.2
The key for the integrated management of the disease by local health facilities is the availability of very simple cheap diagnostic tools and safe oral drugs to treat both Trypanosoma brucei rhodesiense and T b gambiense. Finding new diagnostics and drugs will be the key for an achievable and cost effective sustainable elimination. But as a down side of success, entry into the elimination stage might cause control of sleeping sickness to be seen as less of a major public health problem. A low priority is being given to the disease and its research and development.3 The main challenge today is to avoid creating a situation in which the re-emergence of the disease might occur, after huge efforts had been expended in achieving a situation in which we are close to its elimination.
In this context, the Ugandan case is of great interest,1 4 because the possible overlap of T b rhodesiense and T b gambiense could provoke big difficulties for the diagnosis and treatment of patients, taking into account the fact that no easy way exists to identify the two strains of parasites.5 It could also provoke a high burden because the treatments are different.2 A close surveillance of this phenomenon is a priority. In addition, as cattle are the main reservoir of T b rhodesiense, this should encourage authorities to treat cattle systematically to avoid new epidemics.4 This kind of large mass chemotherapy for cattle will be advantageous if done in partnership with the medical sector.
Competing interests None declared.